The API Holdings (PharmEasy), popularly known as Pharmeasy, has become one of India’s most recognized digital healthcare platforms. The company operates in the rapidly expanding online pharmacy and healthcare services sector, connecting consumers with medicines, diagnostics, and teleconsultation services through its digital ecosystem.
As of March 06, 2026, the Pharmeasy unlisted share price is ₹6.05 per share, with a face value of ₹1 per share. The company’s lot size in the unlisted market is 5000 shares, reflecting the trading structure commonly seen in pre-IPO investments. The 52-week high of the Pharmeasy share price is ₹8, while the 52-week low is ₹5, indicating the volatility that has characterized the company’s valuation in the unlisted market.
With increasing investor attention around the Pharmeasy upcoming IPO, the company’s pre-IPO shares continue to attract interest from investors who want early exposure to India’s growing digital healthcare and pharmaceutical distribution market.
The Pharmeasy share price in the unlisted market reflects the company’s evolving financial performance and broader investor sentiment toward digital healthcare startups.
| Particular | Value |
|---|---|
| Pharmeasy Unlisted Share Price | ₹6.05 per share |
| Face Value | ₹1 |
| Lot Size | 5000 Shares |
| 52 Week High | ₹8 |
| 52 Week Low | ₹5 |
| Average Traded Price | ₹5.92 |
| ISIN | INE0DJ201029 |
The price movement in unlisted markets is influenced by company performance, funding rounds, IPO expectations, and liquidity levels.
Pharmeasy, operated by API Holdings, is a health-tech platform that integrates medicine delivery, diagnostics, and healthcare services into one digital ecosystem.
The company has built a massive presence in India’s healthcare industry by offering services such as:
Online medicine delivery
Diagnostic test bookings
Healthcare consultations
Hospital partnerships
Digital pharmacy services
Pharmeasy has grown rapidly by leveraging technology-driven logistics networks and nationwide pharmaceutical supply chains.
The core business model of Pharmeasy revolves around creating an integrated healthcare platform that connects pharmacies, diagnostic labs, hospitals, and consumers.
The company generates revenue from several streams:
Pharmeasy partners with pharmacies across India and provides doorstep medicine delivery through its mobile application and website.
Through partnerships with diagnostic providers, the platform allows users to book blood tests, health packages, and lab investigations online.
The company also offers teleconsultation services and healthcare product sales, expanding its revenue ecosystem.
Through acquisitions and supply chain integrations, Pharmeasy has strengthened its B2B pharmaceutical distribution network.
The financial profile of API Holdings (Pharmeasy) reflects the characteristics of a high-growth digital startup operating in a competitive healthcare market.
| Financial Metric | Value |
|---|---|
| Total Income | ₹5,898.46 Cr |
| Profit After Tax | -₹1,572.39 Cr |
| EPS | -₹1.05 |
| P/B Ratio | 1.35 |
| Market Capitalisation | ₹3,942.58 Cr |
| Enterprise Value | ₹6,243.75 Cr |
| Book Value | ₹4.5 |
| Intrinsic Value | ₹4.8 |
| Earnings Yield | -17.36% |
While the company is currently reporting losses, it continues to focus on expanding its market share and strengthening its digital healthcare infrastructure.
The company’s revenue growth trajectory highlights the rapid expansion of the digital healthcare market in India.
| Period | Growth |
|---|---|
| 1 Year | 3.62% |
| 3 Years | 0.98% |
| 5 Years | 54.62% |
The strong five-year growth rate of over 54% demonstrates the rapid adoption of online pharmacy and healthcare services in India.
Return on Equity reflects the company’s profitability relative to shareholder investments.
| Year | ROE |
|---|---|
| 2021 | -33.51% |
| 2023 | -110.19% |
| 2025 | -53.66% |
The negative ROE reflects high operating expenses, aggressive expansion, and investments in technology infrastructure.
However, these investments are aimed at long-term market leadership in India’s digital healthcare sector.
Cash flow provides deeper insights into the company’s financial sustainability.
| Cash Flow Type | Amount |
|---|---|
| Cash Flow from Operations | -₹223.53 Cr |
| Cash Flow from Financing | -₹759.91 Cr |
Negative operating cash flows indicate the company is still in its growth phase, focusing on scaling operations and expanding customer acquisition.
The Pharmeasy unlisted share price has experienced fluctuations over recent years.
| Period | CAGR |
|---|---|
| 1 Year | 0% |
| 2 Years | -21.58% |
| 3 Years | -36.48% |
This decline reflects market corrections following the startup valuation boom, along with changes in investor sentiment toward technology startups.
Despite the current financial losses, the company continues to attract attention from investors interested in high-growth technology-driven healthcare companies.
India’s healthcare market is expanding rapidly, with digital platforms becoming increasingly important.
Pharmeasy has become a well-known healthcare brand across major Indian cities.
Millions of users rely on the platform for medicine delivery and diagnostics services.
The company operates across multiple healthcare verticals, strengthening its long-term growth potential.
Investors continue to track Pharmeasy upcoming IPO developments, as a public listing could significantly impact valuation.
The possibility of a Pharmeasy IPO has been discussed widely in the investment community.
A future IPO would provide the company with:
Fresh capital for expansion
Debt reduction opportunities
Improved public market visibility
Enhanced corporate governance
Investors monitoring the Pharmeasy pre IPO market are positioning themselves ahead of any potential listing event.
Investors interested in buying Pharmeasy unlisted shares typically purchase them through specialized brokers that deal in pre IPO investments.
Connect with a broker dealing in unlisted shares
Verify the latest Pharmeasy share price
Place an order for the minimum lot size of 5000 shares
Complete payment and documentation
Shares are transferred to the investor’s Demat account via off-market transfer
This process allows investors to participate in the company’s growth before a potential public listing.
While the company operates in a promising sector, investors should also consider the risks associated with unlisted investments.
Unlisted shares cannot be traded as easily as publicly listed stocks.
The company is currently reporting significant financial losses.
Technology companies often experience sharp valuation fluctuations in private markets.
Understanding these risks is essential before investing in Pharmeasy pre IPO shares.
The long-term outlook for Pharmeasy is closely tied to the evolution of India’s digital healthcare ecosystem.
Key growth drivers include:
Rapid growth of online pharmacy services
Increasing adoption of digital health platforms
Expansion of diagnostic and telemedicine services
Rising healthcare spending in India
If the company successfully strengthens its operational efficiency and profitability, it could become a major player in India’s digital healthcare infrastructure.
The Pharmeasy Unlisted Share Price of ₹6.05 reflects the current market valuation of one of India’s most prominent health-tech companies. Despite short-term financial challenges, the company operates in a high-growth sector with significant long-term potential.
With strong brand recognition, a large customer base, and a rapidly expanding digital healthcare ecosystem, Pharmeasy remains a closely watched company in the pre-IPO market.
Investors monitoring the Pharmeasy share price, Pharmeasy pre IPO shares, and Pharmeasy upcoming IPO developments continue to evaluate the company as a potential long-term growth opportunity in India’s healthcare technology sector.
0 Comments:
Leave a Reply